A clinical study of adenovirus mediated Reduced Expression in Immortalized Cells/Dickkopf-3 (REIC/Dkk-3) gene therapy for malignant pleural mesothelioma.

Trial Profile

A clinical study of adenovirus mediated Reduced Expression in Immortalized Cells/Dickkopf-3 (REIC/Dkk-3) gene therapy for malignant pleural mesothelioma.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 03 Oct 2016

At a glance

  • Drugs Ad SGE DKK3 gene therapy-Kyorin (Primary)
  • Indications Pleural disorders
  • Focus Adverse reactions
  • Most Recent Events

    • 29 Sep 2016 Status changed from recruiting to discontinued.
    • 18 Apr 2015 Status changed from suspended to recruiting as reported by University Hospital Medical Information Network.
    • 17 Nov 2014 Status changed from recruiting to suspended as reported by University Hospital Medical Information Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top